Literature DB >> 390116

Disposition of valproic acid in the rat: dose-dependent metabolism, distribution, enterohepatic recirculation and choleretic effect.

R G Dickinson, R C Harland, A M Ilias, R M Rodgers, S N Kaufman, R K Lynn, N Gerber.   

Abstract

A specific gas chromatographic assay has been developed for measurement of valproic acid (VPA) and its major conjugated metabolites. In rats given single intravenous doses, the decline in blood concentration of VPA was dose-dependent and followed first-order kinetics only at the lowest dose. The time required for the maximum concentration of VPA, after completion of the brief distribution phase, to decline by 50% was 11.7, 41 and 125 min at doses of 15, 150 and 600 mg of NaVPA per kg, respectively. A secondary increase in drug concentration, abolished by exteriorization of the bile, was observed in all intact rats with all doses. Some 45 to 55% of the dose appeared in the bile in 5 hr as VPA glucuronide. Urinary excretion of VPA glucuronide in intact animals accounted for 23 and 51% of the 15 and 150 mg/kg doses, respectively. Tissue distribution studies in rats sacrificed 20 and 90 min after dosage with [14C] NaVPA (150 mg/kg) showed that the drug concentration was highest in blood, moderate in liver, kidney, heart and lung and low in brain, fat, testis and skeletal muscle. During this interval the drug concentration declined in all tissues, whereas the total conjugated metabolites in the small intestine increased from 7 to 28% of the administered dose. The large intestine contained 30 times as much free drug as conjugate. Reabsorption of free VPA, released by hydrolysis of conjugate in the large bowel, accounted for the secondary rise in concentration of VPA observed in blood after single doses. The major urinary metabolites, VPA-glucuronide and 2-n-propylgutaric acid, were identified by gas chromatography/chemical ionization mass spectrometry. Sodium VPA caused a dose-dependent stimulation of bile flow, the magnitude and duration of which closely followed the blood concentration of VPA.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 390116

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

1.  The influence of distributional kinetics into a peripheral compartment on the pharmacokinetics of substrate partitioning between blood and brain tissue.

Authors:  Jeannie M Padowski; Gary M Pollack
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-09       Impact factor: 2.745

2.  Pharmacokinetics, anticonvulsant efficacy, and adverse effects of trans-2-en-valproate after acute and chronic administration in amygdala-kindled rats.

Authors:  D Hönack; C Rundfeldt; W Löscher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

3.  Chronic administration of valproic acid induces a decrease in rat striatal glutamate and taurine levels.

Authors:  G B Acosta; S I Wikinski; C C Bonelli; M C Rubio
Journal:  Amino Acids       Date:  1996-06       Impact factor: 3.520

Review 4.  Cellular compartments of GABA in brain and their relationship to anticonvulsant activity.

Authors:  M J Iadarola; K Gale
Journal:  Mol Cell Biochem       Date:  1981-09-25       Impact factor: 3.396

5.  Physiologically based pharmacokinetic tissue compartment model selection in drug development and risk assessment.

Authors:  Matthew D Thompson; Daniel A Beard
Journal:  J Pharm Sci       Date:  2011-10-03       Impact factor: 3.534

6.  Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat.

Authors:  G M Pollack; K L Brouwer
Journal:  J Pharmacokinet Biopharm       Date:  1991-04

7.  Glucuronidation metabolic kinetics of valproate in guinea pigs: nonlinear at clinical concentration levels.

Authors:  H Y Yu; Y Z Shen
Journal:  Pharm Res       Date:  1996-08       Impact factor: 4.200

8.  14C-NaVP and 14C-PEV repeated dose study in rat. Pharmacokinetic study in rats after repeated oral administrations of 14C-valproic acid sodium salt and 14C-valproic acid pivaloyl oxymethyl ester.

Authors:  M Bertolino; D Acerbi; S Canali; C Giachetti; G Poli; P Ventura; G Zanolo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

9.  Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats.

Authors:  S Kojima; M Nadai; K Kitaichi; L Wang; T Nabeshima; T Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 10.  Valproate-associated hepatotoxicity and its biochemical mechanisms.

Authors:  M J Eadie; W D Hooper; R G Dickinson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.